Please Wait.....
Report
Australia Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 68 Pages I Mordor Intelligence
Australia Drug Delivery Devices Market Analysis
The Australia drug delivery devices market is valued at USD 4.59 billion in 2025 and is forecast to climb to USD 6.85 billion by 2030, registering an 8.31% CAGR over the period. Growth is underpinned by an aging population, a rising chronic-disease burden, and widespread use of the Pharmaceutical Benefits Scheme (PBS), which dispensed medicines to nearly 70% of residents during 2022. Government programs that shift care from hospitals to homes, such as Victoria's Better at Home initiative, further expand demand for user-friendly devices.Intensifying R&D around microneedle patches, connected injectors, and orally delivered biologics is driving product innovation, while digital health investments are improving data flow and remote monitoring capability. Against this backdrop, manufacturers face higher Therapeutic Goods Administration (TGA) fees and strict combination-product rules that lift compliance costs.
Australia Drug Delivery Devices Market Trends and Insights
High Burden of Chronic Diseases and Ageing Population
Australia's 1.3 million people living with diabetes in 2024 generated AUD 3.9 billion in direct health spending aihw.gov.au. Three-quarters of adults were dispensed at least one PBS medicine, and more than 85% of those with chronic conditions required ongoing pharmacotherapy.Age-related physiological changes alter drug absorption and clearance, heightening demand for delivery formats that optimise dosing precision and safety. Manufacturers that tailor devices to geriatric needs-larger buttons, audible cues, and connected adherence alerts-stand to gain as the senior cohort expands.
Government and Market Players Support for At-home Care & Remote Drug Delivery
Victoria's Better at Home program channels AUD 698 million into virtual and in-home healthcare, serving more than 15,000 people a year. Queensland added AUD 27 million for similar services in its 2024-25 budget. Hospital-at-home models have lowered care costs by 30% while maintaining or improving outcomes, leading payers to reimburse home episodes at inpatient rates commonwealthfund.org. These policies create fertile ground for self-use injectors, wearable pumps, and connected inhalers that help patients manage therapy outside acute facilities.
Stringent TGA Combination-Product Compliance Costs
Application fees for new chemical entities included in a device run to AUD 18,872, with evaluation charges of AUD 76,055 and annual levies topping AUD 1,500 for Class III devices. These rising costs weigh heavily on start-ups and academic spin-outs, delaying market entry and, in some cases, redirecting R&D overseas.
Other drivers and restraints analyzed in the detailed report include:
Rising Penetration of Biosimilars and Targeted Therapies Requiring Novel Delivery Formats / Digital Health Integration with Connected Injectors & Pumps / Needlestick Injury Litigation and Risks Associated with Various Devices /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectable systems held 31.63% of the Australia drug delivery devices market share in 2024, a position cemented by growing biologics use and rising chronic-disease prevalence. Connected pen injectors that transmit dosage logs to clinician dashboards are gaining traction among endocrinologists and rheumatologists. The Australia drug delivery devices market size attached to transdermal patches is projected to grow at 12.29% CAGR between 2025 and 2030, spurred by microneedle breakthroughs that improve payload capacity without compromising comfort. Collaboration between the Transdermal and Transmucosal Drug Delivery Research Group and Bionyeri Pty Ltd created a microneedle patch for acute pain episodes, illustrating domestic innovation.
Infusion-pump makers are integrating Bluetooth and closed-loop algorithms in anticipation of a national subsidy for insulin pumps proposed to begin mid-2025. Implantables, ocular inserts, and nasal devices round out the portfolio, each targeting niche clinical requirements. A recent health-technology assessment found intrathecal pumps improve quality of life for refractory cancer pain, though upfront costs remain high.
Injectables delivered 44.57% of 2024 revenue within the Australia drug delivery devices market. High therapy adherence rates and predictable pharmacokinetics keep parenteral administration the default for many biologics. Inhalation devices account for a sizeable fraction, supported by ongoing upgrades to dry-powder carriers for obstructive-airway disease. The oral-mucosal channel is forecast to post a 10.23% CAGR as developers exploit sublingual routes to bypass first-pass metabolism.
Transdermal technologies continue to benefit from work on novel permeation enhancers and herbal patches that reduce gastrointestinal side effects. Nasal formulations appeal to neurologists for rapid central-nervous-system access; nanoparticle-gel hybrids recently showed 86%-96% encapsulation efficiency, signalling commercial promise.
The Australia Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Cancer, Cardiovascular, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Beckton Dickinson / GlaxoSmithKline / Novartis / Terumo / Novo Nordisk / Johnson & Johnson (Johnson MedTech & Janssen) / Sanofi / Pfizer / AstraZeneca / Viatris / Teva Pharmaceutical Industries / Bayer / Medtronic / Insulet / Tandem Diabetes Care / Roche / West Pharmaceutical Services / Gerresheimer / Ypsomed / B. Braun Australia Pty Ltd /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Chrnoic Diseases and Ageing-Population
4.2.2 Government and Market Players Support for At-home Care and Remote Drug Delivery
4.2.3 Rising Penetration of Biosimilars and Targeted Therapies Requiring Novel Delivery Formats
4.2.4 Digital Health Integration with Connected Injectors & Pumps
4.2.5 Community Pharmacy Vaccination Programs Boosting Self-Injection
4.2.6 Accelerated Pipeline Drugs and TGA Fast-track Drugs
4.3 Market Restraints
4.3.1 Stringent TGA Combination-Product Compliance Costs
4.3.2 Needlestick Injury Litigation and Risks Associatied with Various Devices
4.3.3 Concerns Over Data Security and Patient Privacy in Connected/ smart devices
4.3.4 Limited Reimbursement for Implantable Delivery Systems
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral Mucosal (Buccal & Sublingual)
5.2.5 Ocular
5.2.6 Nasal
5.3 By Application
5.3.1 Cancer
5.3.2 Cardiovascular
5.3.3 Diabetes
5.3.4 Infectious Diseases
5.3.5 Other Applications
5.4 By End User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centres
5.4.3 Home Healthcare Settings
5.4.4 Specialty Clinics
5.4.5 Other End Users
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Becton, Dickinson & Company
6.4.2 GlaxoSmithKline plc
6.4.3 Novartis AG
6.4.4 Terumo Corporation
6.4.5 Novo Nordisk A/S
6.4.6 Johnson & Johnson (Johnson MedTech & Janssen)
6.4.7 Sanofi SA
6.4.8 Pfizer Inc.
6.4.9 AstraZeneca plc
6.4.10 Viatris Inc.
6.4.11 Teva Pharmaceutical Industries Ltd
6.4.12 Bayer AG
6.4.13 Medtronic plc
6.4.14 Insulet Corporation
6.4.15 Tandem Diabetes Care Inc.
6.4.16 F. Hoffmann-La Roche Ltd
6.4.17 West Pharmaceutical Services Inc.
6.4.18 Gerresheimer AG
6.4.19 Ypsomed
6.4.20 B. Braun Australia Pty Ltd
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security